top of page

Genetron Holdings, Ltd.



Genetron Holdings, Ltd. ("Genetron") is a leading precision oncology platform company in China that specializes in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. Genetron has developed a comprehensive product and service portfolio that cover the full-cycle of cancer care from early screening, to diagnosis and treatment recommendations, to continuous monitoring and continuous care.
Genetron is driven by its mission to transform cancer treatment and prevention globally by driving technological innovation and accelerating the adoption of precision oncology medicine. It offers its products and services through three business units: diagnosis and monitoring, early screening, and development services.
Genetron's comprehensive diagnostic services and products cover eight out of the top ten major cancers in China, capable of analyzing from focused gene panels to whole exome of approximately 21,000 genes. Depending on the nature of cancer and service types, it offers tissue biopsy, liquid biopsy, or both, providing great flexibility to patients and physicians to achieve the best clinical outcome.
On the frontier of early screening, Genetron has developed a leading technology platform and achieved breakthrough with its proprietary HCCscreen assays that enable early detection and intervention of liver cancer. Liver cancer is highly correlated with HBV infection, and China has approximately 73.9 million HBV carriers, representing significant market potential for precision early screening products.
Genetron collaborates with biopharmaceutical companies, hospitals and research institutions both in China and globally to serve their needs in genomics research and clinical development. Its products and services may be used by biopharmaceutical companies for a range of applications, including biomarker evaluation for molecularly targeted therapy and immuno-therapy, clinical trial enrollment, companion diagnostics development, and joint marketing post-drug approval. Genetron believes its collaboration with biopharmaceutical companies will also build evidence of clinical utility for its platform as an effective diagnostic for advanced cancer therapies.
Genetron believes advancing its services and products can expand the scope of precision oncology medicine to diagnosis, early screening, monitoring and continuous care, improve clinical outcomes, and reduce overall cancer treatment costs.

Key Facts


Public Listing



Location of Key Operations

IR Contact

Pricewaterhousecoopers Zhong Tian LLP

IPO (June 19, 2020)

Cayman Islands

Beijing, China

6 Labs: Beijing, Shanghai, Hangzhou, Chongqing, Guangzhou, Maryland

Hoki Luk, Internal


Analyst Coverage

Latest News

bottom of page